ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: fraud By Trainee Leads Collins To Retract Five Paper; Weinstein Retires At Columbia

November 1, 1996

Abstracts Of Papers From Therapeutic Radiology Meeting

November 21, 1975

Hugh Creech, Fox Chase Chemotherapy Pioneer, Dead at 92

January 31, 2003

Funding Opportunities

November 2, 2002

Pharmaceutical Industry: IVAX Official Broder Objects To Orphan Drug Policies of FDA

May 9, 1997

NCI Cooperative Group Clinical Trials Approved

July 31, 2009